IPT-803

IPT-803
Clinical data
Other namesIPT803
Routes of
administration		Unspecified[1][2]
Drug classDopamine modulator; Opioid receptor antagonist
ATC code
  • None

IPT-803 is a drug described as a dopamine modulator and opioid receptor antagonist which is or was under development for the treatment of Parkinson's disease.[1][3][2][4][5] It is under development by Tools4Patient.[1][3][2] The drug's exact mechanism of action is unclear, but may involve dopamine and endorphin pathways.[4] As of June 2020, it is in phase 1/2 clinical trials.[1][3][2][4] There have been no more recent developments since then.[1][3][2] The chemical structure of IPT-803 does not yet appear to have been disclosed.[1][2]

See also

References

  1. 1 2 3 4 5 6 "IPT 803". AdisInsight. 23 June 2020. Retrieved 1 February 2026.
  2. 1 2 3 4 5 6 "IPT-803 Drug Profile". Ozmosi. 1 January 1900. Retrieved 1 February 2026.
  3. 1 2 3 4 "Delving into the Latest Updates on IPT-803 with Synapse". Synapse. 8 May 2025. Retrieved 1 February 2026.
  4. 1 2 3 Gros P, Garcia LA, Fox SH (May 2025). "Experimental Therapeutics in Parkinson's Disease: A Review". Neurologic Clinics. 43 (2): 399–426. doi:10.1016/j.ncl.2024.12.013. PMID 40185528.
  5. ↑ "A Study to Investigate a New Treatment in Patients With Parkinson's Disease". ClinicalTrials.gov. 13 June 2020. Retrieved 1 February 2026.
This page is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.